Alaethes Wealth LLC Raises Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Alaethes Wealth LLC grew its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 0.8% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 5,449 shares of the medical equipment provider’s stock after buying an additional 41 shares during the quarter. Intuitive Surgical accounts for approximately 1.0% of Alaethes Wealth LLC’s portfolio, making the stock its 26th biggest position. Alaethes Wealth LLC’s holdings in Intuitive Surgical were worth $2,424,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Vanguard Group Inc. lifted its stake in Intuitive Surgical by 1.6% in the first quarter. Vanguard Group Inc. now owns 30,868,620 shares of the medical equipment provider’s stock worth $12,319,358,000 after acquiring an additional 493,126 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Intuitive Surgical by 1.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 16,973,266 shares of the medical equipment provider’s stock worth $5,726,102,000 after purchasing an additional 272,741 shares during the last quarter. Capital World Investors lifted its position in shares of Intuitive Surgical by 1.0% during the 1st quarter. Capital World Investors now owns 7,284,269 shares of the medical equipment provider’s stock worth $2,907,079,000 after purchasing an additional 73,634 shares during the last quarter. Edgewood Management LLC grew its stake in shares of Intuitive Surgical by 7.9% during the fourth quarter. Edgewood Management LLC now owns 5,131,066 shares of the medical equipment provider’s stock worth $1,731,016,000 after purchasing an additional 374,667 shares in the last quarter. Finally, Jennison Associates LLC increased its holdings in Intuitive Surgical by 4.6% in the first quarter. Jennison Associates LLC now owns 4,488,343 shares of the medical equipment provider’s stock valued at $1,791,253,000 after buying an additional 198,483 shares during the last quarter. 83.64% of the stock is owned by institutional investors and hedge funds.

Intuitive Surgical Stock Down 0.8 %

ISRG opened at $486.20 on Friday. Intuitive Surgical, Inc. has a 52 week low of $254.85 and a 52 week high of $496.18. The business has a 50 day moving average price of $468.01 and a two-hundred day moving average price of $424.86. The company has a market cap of $172.46 billion, a PE ratio of 87.76, a P/E/G ratio of 5.41 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 EPS for the quarter, topping the consensus estimate of $1.54 by $0.24. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The business had revenue of $2.01 billion during the quarter, compared to analysts’ expectations of $1.97 billion. During the same quarter in the prior year, the business earned $1.18 earnings per share. The company’s quarterly revenue was up 14.5% compared to the same quarter last year. As a group, sell-side analysts expect that Intuitive Surgical, Inc. will post 5.22 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Craig H. Barratt sold 1,400 shares of Intuitive Surgical stock in a transaction dated Tuesday, July 23rd. The shares were sold at an average price of $458.13, for a total value of $641,382.00. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, Director Craig H. Barratt sold 1,400 shares of the stock in a transaction that occurred on Tuesday, July 23rd. The stock was sold at an average price of $458.13, for a total transaction of $641,382.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Mark Brosius sold 2,115 shares of Intuitive Surgical stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $491.91, for a total value of $1,040,389.65. Following the completion of the sale, the insider now owns 295 shares in the company, valued at $145,113.45. The disclosure for this sale can be found here. In the last quarter, insiders sold 53,120 shares of company stock worth $25,528,753. 0.90% of the stock is owned by insiders.

Analyst Ratings Changes

A number of brokerages have issued reports on ISRG. JPMorgan Chase & Co. lifted their price target on Intuitive Surgical from $475.00 to $495.00 and gave the stock an “overweight” rating in a report on Friday, July 19th. Truist Financial boosted their target price on Intuitive Surgical from $450.00 to $515.00 and gave the stock a “buy” rating in a research note on Tuesday, July 16th. Redburn Atlantic upgraded shares of Intuitive Surgical from a “neutral” rating to a “buy” rating and increased their price target for the company from $380.00 to $510.00 in a research note on Friday, August 2nd. Stifel Nicolaus boosted their price objective on shares of Intuitive Surgical from $430.00 to $475.00 and gave the stock a “buy” rating in a research report on Friday, July 19th. Finally, The Goldman Sachs Group started coverage on shares of Intuitive Surgical in a report on Thursday, May 30th. They issued a “buy” rating and a $500.00 target price for the company. Six equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $446.45.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.